Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.065 USD | +3.25% | +56.62% | -20.22% |
May. 02 | Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding | CI |
Apr. 30 | Top Midday Gainers | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.64M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -26M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.21
x | P/E ratio 2025 * |
-0.48
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.08% |
Latest transcript on Cyclacel Pharmaceuticals, Inc.
1 day | -19.68% | ||
1 week | +32.45% | ||
Current month | -5.66% | ||
1 month | -4.76% | ||
3 months | -22.48% | ||
6 months | -77.05% | ||
Current year | -25.09% |
Managers | Title | Age | Since |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-12-31 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 83 | 06-02-28 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-12-16 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 97-07-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 2.11 | +5.50% | 187 809 |
24-05-03 | 2 | -19.68% | 566,976 |
24-05-02 | 2.49 | -6.04% | 1,822,434 |
24-05-01 | 2.65 | +25.00% | 17,564,410 |
24-04-30 | 2.12 | +55.88% | 21,341,075 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.09% | 2.64M | |
+8.96% | 105B | |
-1.43% | 104B | |
+5.30% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- CYCC Stock